Centessa Pharmaceuticals plc (CNTA) Research
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Market snapshot
- Symbol
- CNTA
- Price
- $40.02
- Day change
- +0.38%
- Market cap
- $6.2B
- P/E ratio
- -24.52x
- 52-week range
- 12.3-40.26
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $39.50
Recent news
- Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash, with a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition adds Centessa's sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly's neuroscience business.
- Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
- Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Eli Lilly and Co (NYSE:LLY) said on Tuesday it will acquire Centessa Pharmaceuticals PLC (NASDAQ:CNTA) for $38 per share in cash, with a potential...
Peer companies
Recent insider activity
- Accardi Mario Alberto — F-InKind (604 shares) on 2026-05-01
- Anderson Karen M. — M-Exempt (41076 shares) on 2026-03-26
- Anderson Karen M. — M-Exempt (41076 shares) on 2026-03-26
- Anderson Karen M. — S-Sale (41076 shares) on 2026-03-26
- Weinhoff Gregory M — M-Exempt (23998 shares) on 2026-03-26
Open Centessa Pharmaceuticals plc (CNTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.